Short Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Drops By 32.7%

Hookipa Pharma Inc (NASDAQ:HOOK) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 30,300 shares, a decline of 32.7% from the November 30th total of 45,000 shares. Based on an average trading volume of 53,000 shares, the short-interest ratio is presently 0.6 days. Approximately 0.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. JMP Securities dropped their target price on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, November 21st. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $48.00 to $2.00 in a report on Friday, December 20th.

Hedge Funds Weigh In On Hookipa Pharma

A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the period. Ikarian Capital LLC bought a new stake in shares of Hookipa Pharma in the 3rd quarter valued at $228,000. Finally, Acadian Asset Management LLC increased its position in shares of Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after buying an additional 108,844 shares during the period. 63.88% of the stock is currently owned by institutional investors.

Hookipa Pharma Price Performance

NASDAQ HOOK traded up $0.09 on Friday, reaching $1.94. The company had a trading volume of 144,427 shares, compared to its average volume of 59,105. The firm has a market cap of $23.39 million, a price-to-earnings ratio of -0.52 and a beta of 0.71. Hookipa Pharma has a fifty-two week low of $1.75 and a fifty-two week high of $10.50. The business has a 50 day moving average of $2.86 and a two-hundred day moving average of $4.48.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.